NCT05167240 (ABMP COVID-19) is a clinical trial in Ambulatory Blood Pressure, sponsored by National Institute of Cardiology, Warsaw, Poland.

Who is sponsoring NCT05167240?

NCT05167240 is sponsored by National Institute of Cardiology, Warsaw, Poland.

What condition does NCT05167240 study?

NCT05167240 studies Ambulatory Blood Pressure.

Is NCT05167240 still recruiting?

NCT05167240 is currently status unknown. Last updated 22 December 2021.

Last reviewed 2021-12-22 · How we verify

NCT05167240: ABMP COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ESH ABPM COVID-19 STUDY

Status unknown Last updated 22 December 2021

What this trial tests

trial in Ambulatory Blood Pressure in 500 participants. Status unknown.

Timeline

3 December 2021

Primary endpoint
3 June 2022

30 December 2022

Quick facts

Lead sponsor	National Institute of Cardiology, Warsaw, Poland
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	3 December 2021
Primary completion	3 June 2022
Estimated completion	30 December 2022
Sites	1 location across Poland

Conditions studied

Ambulatory Blood Pressure — all drugs for Ambulatory Blood Pressure →

Sponsor

National Institute of Cardiology, Warsaw, Poland

Who can join

18 and older, any sex, with Ambulatory Blood Pressure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of the study is to determine the impact of the COVID-19 pandemic on blood pressure profiles and variability as assessed by ambulatory blood pressure monitoring (ABPM) through the comparison of ABPM data obtained before and during the COVID-19 lockdown in already treated hypertensive patients

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications.
Karagiannidis AG, Theodorakopoulou MP, Ferro CJ, Ortiz A, et al · · 2023 · cited 7× · PMID 36998307 · DOI 10.1093/ckj/sfac235

Verify or expand the search:

Other recruiting trials for Ambulatory Blood Pressure

Currently open trials in the same condition.

NCT03868384 — The Effect of Home Blood Pressure Measurement on the Management of Hypertension · active not recruiting

Other National Institute of Cardiology, Warsaw, Poland trials

Trials by the same sponsor.

NCT07450287 — CardioNETPOL National Registry of Carcinoid Heart Disease · not yet recruiting
NCT07144189 — AI Assessment of Low-Gradient Aortic Stenosis Severity Based on Echocardiography · recruiting
NCT06878729 — Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI · NA · recruiting
NCT07254572 — Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes · Phase 4 · recruiting
NCT06275763 — Optimal Medical Treatment of Difficult-to-treat Hypertension · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05167240 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Cardiology, Warsaw, Poland
Last refreshed: 22 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05167240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing